NVCR Stock: Price, Earnings History and SEC Filings
NovoCure Limited (NVCR) last traded at $13.15, up 0.31% on the latest session and down 17.6% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-0.09 against an analyst estimate of $-0.21, a beat of 57.1%.
$13.15 +0.31%
1 month-17.55%
52-week high$21.45
52-week low$9.82
Volume1.97M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NVCR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-0.09 | $-0.21 | +57.14% |
| Jun 2026 | Jul 23, 2026 | $-0.13 | $-0.30 | +56.67% |
| Mar 2026 | Apr 30, 2026 | $-0.62 | $-0.40 | -55.00% |
| Dec 2025 | Feb 26, 2026 | $-0.22 | $-0.41 | +46.34% |
NVCR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NVCR
SEC filing data is not available right now. You can search for NVCR on SEC EDGAR.
NVCR news
- NovoCure (NVCR) Q3 Results Spark Margin Turn DebateOct 31, 2026 · finance.yahoo.com
- NovoCure Stock Is In Focus After Earnings Beat And Slower Optune Pax LaunchOct 30, 2026 · finance.yahoo.com
- NovoCure Q3 Earnings Call HighlightsOct 29, 2026 · marketbeat.com
- NovoCure (NVCR) Q3 2026 Earnings Call TranscriptOct 29, 2026 · fool.com
- Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct CompetitionOct 29, 2026 · stocktwits.com
- NovoCure Sinks 5% Despite Guidance Raise as Pancreatic Cancer Launch Access Is “Significantly Limited”Oct 29, 2026 · tikr.com
- NovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- NovoCure: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About NovoCure Limited
NovoCure Limited (NVCR) is a US-listed public company on Nasdaq.